Inactivating mutations in the beta cell KATP channels are the most common cause of congenital hyperinsulinism (HI), accounting for approximately 60% of all cases with known genotype. The beta cell KATP channels play a very important role in the regulation of insulin secretion by coupling the metabolic state of the cell to membrane potential.

Unrecognized or inadequately treated hyperinsulinism (HI) poses a high risk of adverse neurodevelopmental outcomes due to the combined insult of hypoglycemia and lack of alternate brain fuels.

The Congenital Hyperinsulinism Center at Children’s Hospital of Philadelphia, with a high volume of approximately 80 congenital hyperinsulinism (HI) cases a year, sees a large share of unusual cases.

Nancy Andrews shares her story about how her son’s multiple surgeries at CHOP inspired her family to give back.

The children of Vera Barksdale Johnson, CHOP’s first Emergency Department social worker, celebrate her joyful life and groundbreaking career through philanthropy.

CHOP’s First Episode Psychosis Program offers collaborative therapies that put youth on paths to better outcomes.

The Movement Disorders Program is one of the only programs of its kind in the country and provides life-changing results.

For 22 years, collaborative research at CHOP’s Biesecker Pediatric Liver Center has been changing the future for children with serious liver diseases.

Anne Ades, MD, MSEd, serves as Medical Co-Director of CHOP’s Center for Simulation, Advanced Education and Innovation, which uses computerized medical manikins to teach medical procedures. This is a day in her life.

Children’s Hospital of Philadelphia (CHOP) today announced that it has received more than $10 million in a series of gifts to fund critical neurofibromatosis research from the Gilbert Family Foundation, a private foundation established by Dan and Jennifer Gilbert to accelerate a cure for neurofibromatosis type 1 (NF1).